PMID- 28642591
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20190102
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 32
IP  - 2
DP  - 2018 Feb
TI  - Donor and recipient age, gender and ABO incompatibility regardless of donor 
      source: validated criteria for donor selection for haematopoietic transplants.
PG  - 492-498
LID - 10.1038/leu.2017.199 [doi]
AB  - Prior data indicate similar outcomes after transplants from human leukocyte 
      antigen (HLA)-haplotype-matched relatives, HLA-identical siblings and HLA-matched 
      unrelated donors. We used our prospective data set to answer a clinically 
      important question: who is the best donor for a person with acute leukaemia 
      transplanted in first complete remission. Patients were randomly divided into 
      training (n=611) and validation (n=588) sets. A total of 1199 consecutive 
      subjects received a transplant from an HLA-haplotype-matched relative using 
      granulocyte colony-stimulating factor and anti-thymocyte globulin (n=685) or an 
      HLA-identical sibling (n=514); 3-year leukaemia-free survivals (LFSs) were 75 and 
      74% (P=0.95), respectively. The multivariate model identified three major risk 
      factors for transplant-related mortality (TRM): older donor/recipient age, 
      female-to-male transplants and donor-recipient ABO major-mismatch transplants. A 
      risk score was developed based on these three features. TRMs were 8%, 15% and 31% 
      for subjects with scores of 0-1, 2 and 3, respectively, (P<0.001). Three-year 
      LFSs were 78%, 74% and 58%, respectively, (P=0.003). The risk score was validated 
      in an independent cohort. In conclusion, our data confirm donor source is not 
      significantly correlated with transplant outcomes. Selection of the best donor 
      needs to consider donor-recipient age, matching for gender and ABO 
      incompatibility among persons with acute leukaemia receiving related transplants 
      under our transplant modality.
FAU - Wang, Y
AU  - Wang Y
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Wu, D-P
AU  - Wu DP
AD  - The First Affiliated Hospital of Soochow University, Suzhou, China.
FAU - Liu, Q-F
AU  - Liu QF
AD  - Nanfang Hospital, Southern Medical University, Guangzhou, China.
FAU - Xu, L-P
AU  - Xu LP
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Liu, K-Y
AU  - Liu KY
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Zhang, X-H
AU  - Zhang XH
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Xu, Y
AU  - Xu Y
AD  - The First Affiliated Hospital of Soochow University, Suzhou, China.
FAU - Huang, F
AU  - Huang F
AD  - Nanfang Hospital, Southern Medical University, Guangzhou, China.
FAU - Huang, X-J
AU  - Huang XJ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
AD  - Peking-Tsinghua Center for Life Sciences, Beijing, China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170623
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Antilymphocyte Serum)
SB  - IM
MH  - ABO Blood-Group System/*immunology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antilymphocyte Serum/immunology
MH  - Bone Marrow Transplantation/methods
MH  - Child
MH  - Cohort Studies
MH  - Donor Selection/methods
MH  - Female
MH  - Graft Survival/immunology
MH  - Graft vs Host Disease/immunology
MH  - Hematopoietic System/*immunology
MH  - Histocompatibility/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Siblings
MH  - Transplantation, Homologous/methods
MH  - Unrelated Donors
MH  - Young Adult
EDAT- 2017/06/24 06:00
MHDA- 2019/01/03 06:00
CRDT- 2017/06/24 06:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/06/01 00:00 [revised]
PHST- 2017/06/07 00:00 [accepted]
PHST- 2017/06/24 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2017/06/24 06:00 [entrez]
AID - leu2017199 [pii]
AID - 10.1038/leu.2017.199 [doi]
PST - ppublish
SO  - Leukemia. 2018 Feb;32(2):492-498. doi: 10.1038/leu.2017.199. Epub 2017 Jun 23.